financetom
Business
financetom
/
Business
/
OpenAI finalizes 'o3 mini' reasoning AI model version, to launch it soon
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
OpenAI finalizes 'o3 mini' reasoning AI model version, to launch it soon
Jan 17, 2025 3:03 PM

Jan 17 (Reuters) - ChatGPT maker OpenAI has finalized a

version of its new reasoning AI model o3 mini and would be

launching it in a couple of weeks, CEO Sam Altman said on

Friday.

The Microsoft ( MSFT )-backed company has considered user

feedback and, consequently, plans to release the application

programming interface (API) and ChatGPT simultaneously, Altman

wrote in a post on social media platform X.

Last December, OpenAI said it was testing reasoning AI

models, o3 and o3 mini, indicating growing competition with

rivals such as Alphabet's Google to create smarter

models capable of tackling complex problems.

The AI startup had planned to launch o3 mini by the end of

January, and the full o3 thereafter, as more robust large

language models could outperform existing models and attract new

investments and users.

In September 2024, the GenAI pioneer released o1 AI models

designed to spend more time processing queries to solve harder

problems.

The o1 models are capable of reasoning through complex tasks

and can solve more challenging problems than previous models in

science, coding and math, the company had said in a blog post.

The new o3 and o3 mini models would be more powerful than

the previously launched o1 models, the company had said

previously.

Earlier this week, OpenAI said it was introducing a beta

feature called Tasks to ChatGPT, signaling its foray into the

virtual assistant space, competing with Apple's ( AAPL ) Siri

and Amazon's ( AMZN ) Alexa.

The release of ChatGPT in late 2022 sparked a frenzy of

investments in AI firms, with its growing popularity and new

product launches helping OpenAI close a $6.6 billion funding

round in October.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Perrigo Recalls 16,500 Cans of Baby Formula Due to Elevated Vitamin D Levels
Perrigo Recalls 16,500 Cans of Baby Formula Due to Elevated Vitamin D Levels
Aug 9, 2024
08:54 AM EDT, 08/09/2024 (MT Newswires) -- Perrigo ( PRGO ) said Thursday it is voluntarily recalling 16,500 cans of store-brand Premium Infant Formula with iron milk-based powder due to elevated levels of vitamin D. The company said the recalled product was shipped to H-E-B Grocery in Texas and CVS Health ( CVS ) stores in Texas, Florida, California, South...
Why Is Software Company Five9 Stock Diving Premarket Friday?
Why Is Software Company Five9 Stock Diving Premarket Friday?
Aug 9, 2024
Five9 ( FIVN ), Inc. shares are trading lower after the company reported second-quarter 2024 results. Revenue was $252.1 million, beating the consensus of $245.2 million. Adjusted gross margin stood at 60.5%, down from 61.8% last year. Adjusted EBITDA rose to $41.8 million from $41.5 million a year ago. Operating cash flow came in at $19.9 million in the quarter. Adjusted...
ADENTRA Books Higher Q2 Adjusted Net Income
ADENTRA Books Higher Q2 Adjusted Net Income
Aug 9, 2024
08:51 AM EDT, 08/09/2024 (MT Newswires) -- ADENTRA ( HDIUF ) , a distributor of architectural building products, said overnight Thursday that its adjusted net income increased 47% in the second quarter. Adjusted net income rose to $24.4 million from $16.6 million. Sales slipped to US$549.5 million from US$585.9 million while adjusted EBITDA grew 5.1% to US$48.5 million. From an...
AN2 Therapeutics to Discontinue Clinical Study of Lung Disease Drug Candidate Epetraborole; Shares Plunge Pre-Bell
AN2 Therapeutics to Discontinue Clinical Study of Lung Disease Drug Candidate Epetraborole; Shares Plunge Pre-Bell
Aug 9, 2024
08:52 AM EDT, 08/09/2024 (MT Newswires) -- AN2 Therapeutics ( ANTX ) said Friday it will discontinue the phase 2 and 3 of its EBO-301 study of epetraborole, which is intended for treating refractory Mycobacterium avium complex lung disease. The announcement was made as the company released topline data from its phase 2 trial of the drug candidate. Based on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved